EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular Engineering of Aptamers for Glioblastoma Therapy: From Simple Antagonists to AI-Driven Approaches, a Narrative Review

Luana Di Leandro, Martina Colasante iD, Mariano Catanesi, Francesco Giansanti, Annamaria Cimini iD, Michele D'Angelo iD, Vanessa Castelli iD, Rocco Savino, Rodolfo Ippoliti

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27188231 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Luana Di Leandro und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ITALIAN UNIVERSITY AND RESEARCH (MUR) NATIONAL INNOVATION ECOSYSTEM, DEPARTMENT OF LIFE, HEALTH AND ENVIRONMENTAL SCIENCES, UNIVERSITY OF L'AQUILA, European Union—NextGenerationEU under the Italian University and Research (MUR) National Innovation Ecosystem.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma multiforme (GBM) is an extremely aggressive and lethal brain tumor, characterized by marked molecular heterogeneity, the persistence of glioma stem cells (GSCs), and the limited permeability of the blood–brain barrier (BBB), which collectively hinder therapeutic efficacy. To address these barriers, nucleic acid aptamers, short single-stranded oligonucleotides with high affinity and specificity for molecular targets, have emerged as a promising therapeutic platform. Early unmodified aptamers, such as AS1411 and U2, demonstrated target engagement but showed limited performance due to instability and rapid systemic clearance. Chemical modifications, including 2′-fluoro substitutions and PEGylation, resulted in improved stability, specificity, and pharmacokinetic properties, enabling the development of innovative aptamer drug conjugates (ApDCs) for targeted delivery to GBM cells. In parallel, multivalent aptamer architectures, such as bispecific aptamer targeting entities (BATEs) and aptamer guided nanostructures, have been designed to enhance binding avidity, address tumor heterogeneity, and facilitate BBB transcytosis. More recently, computational strategies ranging from machine learning-guided sequence optimization to structure prediction and generative AI have accelerated the rational design of aptamers tailored to GBM specific challenges. This review examines these advances, the remaining pharmacological limitations, and the potential of computational tools to reshape the future of aptamer based GBM therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aptamers, NucleotideGlioblastomaBrain NeoplasmsHumansAnimalsBlood-Brain BarrierAntineoplastic AgentsDrug Delivery SystemsMachine LearningArtificial Intelligence

Stichwörter der Autor:innen

aptamersgenerative machine learningglioblastomananostructurestargeted drug delivery

Substanzen

Aptamers, NucleotideAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
  • Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, Temple University, Philadelphia, PA 19122, USA.
  • Department of Medical and Surgical Sciences, Magna Graecia University, 88100 Catanzaro, Italy.

ORCID-Profile: Martina Colasante, Annamaria Cimini, Michele D'Angelo, Vanessa Castelli

Förderung

  • ITALIAN UNIVERSITY AND RESEARCH (MUR) NATIONAL INNOVATION ECOSYSTEM
  • DEPARTMENT OF LIFE, HEALTH AND ENVIRONMENTAL SCIENCES, UNIVERSITY OF L'AQUILA
  • European Union—NextGenerationEU under the Italian University and Research (MUR) National Innovation Ecosystem
  • University of L’Aquila

Zitieren

APA

Di Leandro, L., Colasante, M., Catanesi, M., Giansanti, F., Cimini, A., D'Angelo, M., Castelli, V., Savino, R., & Ippoliti, R. (2026). Molecular Engineering of Aptamers for Glioblastoma Therapy: From Simple Antagonists to AI-Driven Approaches, a Narrative Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188231

Vancouver

Di Leandro L, Colasante M, Catanesi M, Giansanti F, Cimini A, D'Angelo M, et al. Molecular Engineering of Aptamers for Glioblastoma Therapy: From Simple Antagonists to AI-Driven Approaches, a Narrative Review. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188231

BibTeX
@article{DiLeandro2026,
  author = {Di Leandro, Luana and Colasante, Martina and Catanesi, Mariano and Giansanti, Francesco and Cimini, Annamaria and D'Angelo, Michele and Castelli, Vanessa and Savino, Rocco and Ippoliti, Rodolfo},
  title = {Molecular Engineering of Aptamers for Glioblastoma Therapy: From Simple Antagonists to AI-Driven Approaches, a Narrative Review},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27188231}
}
Kostenlos starten →